IBREXAFUNGERP - AN OVERVIEW

quinupristin/dalfopristin will increase the amount or outcome of avanafil by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Observe. CYP3A4 inhibitors may perhaps reduce avanafil clearance expanding systemic publicity to avanafil; increased levels may perhaps bring about greater linked adverse events; the most advisable dose o